MD Anderson Cancer CenterHouston, TX
Disclosures:
258 - Exploratory Analysis of Plasma Protein Abundance Kinetics from I-SABR, A Randomized Phase II Trial of Stereotactic Ablative Radiotherapy with or without Nivolumab in Stage I-IIA or Recurrent Non-Small
Tuesday, October 1, 20248:10 AM – 8:20 AM ET
3728 - Assessing the Relationship of Radiation Treatment Breaks with the COVID-19 Pandemic and Overall Survival
Wednesday, October 2, 202410:30 AM – 11:45 AM ET